about
our vision
Redefining Preclinical Drug Development Through Human Diversity
PredictCan Biotechnologies is a biotechnology company pioneering a new generation of
individual-centric preclinical models that bring human biological diversity into drug discovery.
Our patented Cell Educating Technology™ transforms human cell lines into personalized phenotypic models using human serum, enabling pharmaceutical companies to evaluate drug efficacy, predict toxicity, and understand interindividual
variability before clinical trials.
Our Mission
Building Better Models for Better Medicines
Despite remarkable advances in biomedical science, most preclinical models still represent a single biological background. They overlook the diversity that defines real patient populations, limiting the ability to predict clinical outcomes and contributing to costly failures during drug development.
Our mission is to bridge this gap by providing scalable, human-based models that phenotypically reproduce biological diversity, enabling more predictive, efficient, and ethical drug development.
Our Team
LEADERSHIP
Hong Tuan DUONG, PhD
Chief Executive Officer & Co-founder
With more than 20 years of expertise in experimental medicine, liver biology, and innate immunity, Dr. Hong Tuan Duong has built his career at the intersection of fundamental research and translational medicine. After 18 years at the University of Basel in Switzerland, where he developed and supervised research programs on innate immunity and liver diseases and obtained his HDR/PD in Experimental Medicine, he joined INSERM at the University of Strasbourg in France to pursue research in precision oncology. Co-inventor of the patented Cell Educating Technology™, he co-founded PredictCan Biotechnologies, where, as CEO, he leads the company’s scientific strategy and research programs, as well as its overall development strategy.
LEADERSHIP
Sara CHERRADI, PhD
Chief Technical Officer & Co-founder
With more than 10 years of research experience in cancer biology, preclinical drug development, and precision medicine, Dr. Sara Cherradi has built her expertise around the development of patient-relevant models for predicting individual drug response. She received her PhD in Cancer Biology from the University of Montpellier in France and subsequently joined the University of Strasbourg, where she developed expertise in patient-derived models for anticancer drug evaluation and precision medicine. Co-inventor of the patented Cell Educating Technology™, she co-founded PredictCan Biotechnologies, where, as CTO, she leads the company’s technology development and R&D programs, translating scientific concepts into robust and scalable solutions for preclinical drug efficacy and safety assessment.
LEADERSHIP
Anh NGUYEN, PhD
Chief Strategy Officer
With decades of experience in biotechnology entrepreneurship, company building, and strategic development, Dr. Anh Nguyen has built his career transforming scientific innovation into successful biotechnology ventures. A molecular biologist by training, he holds a PhD from the University of California, San Diego and completed the MIT Sloan MBA Program. A serial biotech entrepreneur, he co-founded several successful biotechnology companies, including Syntro and Invitrogen, both of which reached public listings on NASDAQ, and later co-founded MedinCell, where he served as CEO and Chairman and contributed to the company’s strategic development and growth. As Chief Strategy Officer at PredictCan Biotechnologies, he brings his extensive entrepreneurial experience to lead the company’s strategic and financial development, supporting its financing strategy, growth, and long-term value creation.
R&D TEAM
Salomé ROUX
Research Engineer
With a strong background in applied biology, pharmacology, and cellular and molecular biology, Salomé Roux brings extensive technical expertise to PredictCan’s R&D activities. She obtained her Engineering Degree in Applied Biology from Polytech Clermont, France, and subsequently spent four years at CNRS UMR5203 in Montpellier, working in partnership with the biotechnology company Revvity, where she developed solid expertise in pharmacology and cellular and molecular biology. In PredictCan Salomé plays a key role in the development, optimization, and experimental validation of the company’s individual-centric preclinical models, contributing to R&D programs across drug safety and efficacy.
